First Patient Dosed in Immutep’s TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer

Core Insights - Immutep Limited has successfully dosed the first patient in its pivotal TACTI-004 Phase III trial, evaluating eftilagimod alfa in combination with KEYTRUDA and chemotherapy for advanced non-small cell lung cancer (NSCLC) [1][2] Company Overview - Immutep is a late-stage biotechnology company focused on developing immunotherapies for cancer and autoimmune diseases, particularly leveraging LAG-3 to stimulate or suppress immune responses [7] Trial Details - TACTI-004 is a randomized, double-blind, controlled Phase III study that will enroll approximately 756 patients across more than 150 clinical sites in over 25 countries [5][6] - The trial's dual primary endpoints are progression-free survival and overall survival, with patients randomized 1:1 to receive either the treatment combination or a control [6] Market Context - Lung cancer is the leading cause of cancer-related deaths, with an expected increase in incidence to approximately 3 million cases worldwide by 2030; NSCLC accounts for about 80-85% of lung cancer diagnoses [3] - There is a significant unmet need for new treatment options for NSCLC, as less than 30% of patients survive five years post-diagnosis [3] Regulatory and Recruitment Status - Recruitment for TACTI-004 is ongoing, with approvals from various regulatory authorities including Australia, Canada, and several European countries; further approvals are anticipated [2][5]